In the wake of the U.S. Supreme Court’s ruling in Daimler v. Bauman, lawyers for N.J.-based drugmaker Mylan Pharmaceuticals Inc. told a Delaware judge that the company didn’t expect to be sued in the state ever again. That’s because Daimler, which tightened the requirements for a court to assert general jurisdiction, made it much tougher for plaintiffs to sue foreign companies in the U.S., and also to sue U.S. companies outside their home states.
But so far—at least when it comes to patent litigation against Mylan—Delaware judges are refusing to let go.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
